http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104628864-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2013-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104628864-B |
| titleOfInvention | Anti-tumor fusion protein EL-defensin, and coding gene and application thereof |
| abstract | The invention provides an anti-tumor fusion protein, which has the following primary amino acid sequence structure: EGFR specific targeting oligopeptide-connecting peptide 1-prosthetic group protein LDP-connecting peptide 2-defensin HBD-1; wherein, the EGFR specific targeting oligopeptide has an amino acid sequence shown in SEQ ID NO. 1, the prosthetic group protein LDP has an amino acid sequence shown in SEQ ID NO. 2, and the defensin HBD-1 has an amino acid sequence shown in SEQ ID NO. 3. The fusion protein is a novel anti-tumor fusion protein taking prosthetic group protein LDP as a bracket, and has the functions of EGFR targeting and killing tumor cells by defensin HBD-1. The invention also provides a coding gene and a pharmaceutical application of the fusion protein. |
| priorityDate | 2013-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.